Forsta AP Fonden Buys 7,900 Shares of The Cigna Group (NYSE:CI)

Forsta AP Fonden increased its stake in The Cigna Group (NYSE:CI) by 8.8% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 97,500 shares of the health services provider’s stock after purchasing an additional 7,900 shares during the quarter. Forsta AP Fonden’s holdings in The Cigna Group were worth $26,924,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. ORG Wealth Partners LLC purchased a new position in The Cigna Group during the 4th quarter valued at about $34,000. Ulland Investment Advisors LLC grew its stake in The Cigna Group by 2,500.0% during the third quarter. Ulland Investment Advisors LLC now owns 104 shares of the health services provider’s stock valued at $36,000 after acquiring an additional 100 shares in the last quarter. Prospera Private Wealth LLC bought a new stake in The Cigna Group during the 3rd quarter worth approximately $37,000. Harbor Capital Advisors Inc. purchased a new stake in The Cigna Group in the 3rd quarter worth approximately $45,000. Finally, Intact Investment Management Inc. bought a new position in The Cigna Group in the 3rd quarter valued at $69,000. 86.99% of the stock is currently owned by institutional investors.

The Cigna Group Price Performance

CI stock opened at $302.74 on Wednesday. The company has a current ratio of 0.72, a quick ratio of 0.72 and a debt-to-equity ratio of 0.71. The firm’s 50-day moving average price is $296.45 and its two-hundred day moving average price is $325.14. The stock has a market capitalization of $84.21 billion, a price-to-earnings ratio of 28.56, a PEG ratio of 0.78 and a beta of 0.54. The Cigna Group has a 12-month low of $262.03 and a 12-month high of $370.83.

The Cigna Group (NYSE:CI) last released its quarterly earnings results on Thursday, October 31st. The health services provider reported $7.51 EPS for the quarter, beating analysts’ consensus estimates of $7.22 by $0.29. The business had revenue of $63.70 billion during the quarter, compared to analyst estimates of $59.58 billion. The Cigna Group had a return on equity of 18.42% and a net margin of 1.31%. The Cigna Group’s quarterly revenue was up 29.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $6.77 EPS. As a group, equities analysts predict that The Cigna Group will post 28.5 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Stephens reiterated an “overweight” rating and issued a $410.00 price objective on shares of The Cigna Group in a research report on Friday, November 1st. Barclays raised their price target on The Cigna Group from $405.00 to $420.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Piper Sandler reissued an “overweight” rating and set a $394.00 price objective (up previously from $392.00) on shares of The Cigna Group in a report on Tuesday, November 5th. Truist Financial lowered their target price on shares of The Cigna Group from $420.00 to $390.00 and set a “buy” rating on the stock in a research note on Monday, January 6th. Finally, StockNews.com lowered shares of The Cigna Group from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. One investment analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, The Cigna Group currently has a consensus rating of “Buy” and a consensus price target of $395.93.

The Cigna Group Company Profile

The Cigna Group, together with its subsidiaries, provides insurance and related products and services in the United States. Its Evernorth Health Services segment provides a range of coordinated and point solution health services, including pharmacy benefits, home delivery pharmacy, specialty pharmacy, distribution, and care delivery and management solutions to health plans, employers, government organizations, and health care providers.